Treatment of tegumentary leishmaniasis in two hemodialysis patients with end-stage renal disease using two series of pentamidine
- PMID: 33759923
- PMCID: PMC8008861
- DOI: 10.1590/0037-8682-0633-2020
Treatment of tegumentary leishmaniasis in two hemodialysis patients with end-stage renal disease using two series of pentamidine
Abstract
In this study, we present two cases of cutaneous leishmaniasis in patients with end-stage renal disease, who were treated solely with intramuscular pentamidine. In such cases, treatment implies a fine line between therapeutic efficacy and toxicity. This is suggestive of a knowledge gap; however, findings indicate that this is still the fastest and safest alternative to the treatment with antimonials. Also, it can help avoid the side effects that occur upon using antimonials.
Conflict of interest statement
Figures
Similar articles
-
American tegumentary leishmaniasis: severe side effects of pentavalent antimonial in a patient with chronic renal failure.An Bras Dermatol. 2019 Jul 29;94(3):355-357. doi: 10.1590/abd1806-4841.20198388. An Bras Dermatol. 2019. PMID: 31365669 Free PMC article.
-
Rhabdomyolysis associated with pentamidine isethionate therapy for American cutaneous leishmaniasis.J Antimicrob Chemother. 2003 May;51(5):1319-20. doi: 10.1093/jac/dkg195. Epub 2003 Mar 28. J Antimicrob Chemother. 2003. PMID: 12668576 No abstract available.
-
Efficacy of short-course intramuscular pentamidine isethionate treatment on Old World localized cutaneous leishmaniasis in 2 patients.Clin Infect Dis. 2006 Jun 15;42(12):1812-3. doi: 10.1086/504430. Clin Infect Dis. 2006. PMID: 16705598 No abstract available.
-
Efficacy and safety of pentamidine isethionate for tegumentary and visceral human leishmaniasis: a systematic review.J Travel Med. 2021 Aug 27;28(6):taab065. doi: 10.1093/jtm/taab065. J Travel Med. 2021. PMID: 33890115
-
Cutaneous leishmaniasis treatment.Travel Med Infect Dis. 2007 May;5(3):150-8. doi: 10.1016/j.tmaid.2006.09.004. Epub 2006 Oct 31. Travel Med Infect Dis. 2007. PMID: 17448941 Review.
Cited by
-
Successful treatment of meglumine antimoniate in patient with cutaneous leishmaniasis with end-stage renal failure undergoing hemodialysis: a case report.J Med Case Rep. 2025 Jun 16;19(1):277. doi: 10.1186/s13256-025-05331-x. J Med Case Rep. 2025. PMID: 40524186 Free PMC article.
References
-
- Guerra JAO, Barbosa MGV, Vasconcelos ZS, Freitas NS, Fonseca FR, Júnior RCAS, et al. Socioenvironmental aspects of the Purus Region - Brazilian Amazon: Why relate them to the occurrence of American Tegumentary Leishmaniasis? Munderloh UG, compiler. PLoS One. 2019;14(2):e0211785. https://dx.plos.org/10.1371/journal.pone.0211785 - DOI - PMC - PubMed
-
- Basile G, Cristofaro G, Locatello LG, Vellere I, Piccica M, Bresci S, et al. Refractory mucocutaneous leishmaniasis resolved with combination treatment based on intravenous pentamidine, oral azole, aerosolized liposomal amphotericin B, and intralesional meglumine antimoniate. Int J Infect Dis. 2020;97:204–207. - PubMed
-
- Rybniker J, Goede V, Mertens J, Ortmann M, Kulas W, Kochanek M, et al. Treatment of visceral leishmaniasis with intravenous pentamidine and oral fluconazole in an HIV-positive patient with chronic renal failure - a case report and brief review of the litera. Int J Infect Dis. 2010;14(6):e522-5. - PubMed
-
- McGwire BS, Satoskar AR. Leishmaniasis: clinical syndromes and treatment. QJM. 2014;107(1):7–14. http://www.ncbi.nlm.nih.gov/pubmed/23744570 - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous